Cancer drug pharmaceutical companies play a crucial role in developing innovative therapies to combat the rising incidence of cancer globally. As India faces a significant increase in cancer cases, experts predict it may become the “cancer capital of the world.” Factors such as lifestyle changes, environmental pollution, and genetic predisposition contribute to this alarming trend.
In response, Indian pharma companies are ramping up research and development efforts to produce affordable and effective cancer treatments. By focusing on targeted therapies and generics, these companies aim to make life-saving medications accessible to a larger population, addressing the growing cancer burden in the country.
Share Price
The shares of Aurobindo Pharma are currently trading at Rs. 1,260.6 up by 1.52% from its previous close of Rs. 1,241.7 as of December 23, 2024. The stock also touched an intraday high of Rs. 1,265.
Recent Updates
Approval of Bevqolva for Cancer Treatment
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to market its biosimilar version of bevacizumab, called Bevqolva. This drug is used to treat various types of cancer, including colorectal, lung, kidney, cervical, and ovarian cancers. The approval allows Bevqolva to be available in 25 mg/mL concentration for infusion, offered in two vial sizes: 4 mL (100 mg) and 16 mL (400 mg), both designed for vein infusion.
Affordable Treatment Option for Cancer Patients
Bevqolva is a biosimilar to the brand-name drug Avastin and is intended to provide a more affordable option for patients undergoing cancer treatment. Its approval marks an important step in expanding treatment choices for those battling several types of serious cancers.
About CuraTeQ Biologics
CuraTeQ Biologics Private Limited (CuraTeQ), a subsidiary of Aurobindo Pharma Limited, is a global biopharmaceutical company headquartered in Hyderabad, India. CuraTeQ’s vision is to improve the well-being of patients suffering from debilitating illnesses by providing them access to high-quality and cost-effective biosimilars.
It is focused on developing biosimilars for the treatment of various cancers and autoimmune diseases. CuraTeQ’s pipeline consists of fourteen biosimilars, primarily targeting the immunology and oncology segments. It has end-to-end capabilities in producing a full range of products from bulk drug substance to fill finish and packaged drug products.
About Aurobindo Pharma
Aurobindo Pharma Limited, headquartered in Hyderabad, India, is a leading global pharmaceutical company. It develops, manufactures, and markets a wide range of generic drugs, branded specialty pharmaceuticals, and active pharmaceutical ingredients across more than 150 countries.
The company operates 29 manufacturing and packaging facilities approved by top regulatory agencies such as the USFDA, UK MHRA, and Japan PMDA. Aurobindo’s diverse product portfolio spans several therapeutic areas, including CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterology, Anti-Diabetics, and Anti-Allergic.
The company is backed by a strong research and development setup, enabling continued growth and innovation in the pharmaceutical industry.
Written By: Dipangshu Kundu
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
